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With the major attention to the pivotal roles of PPARs in diverse aspects of energy metabolism, the essential functions of PPARγ
and PPARβ/δ in placental development came as a surprise and were often considered a nuisance en route to their genetic analysis.
However, these findings provided an opportune entrée into placental biology. Genetic and pharmacological studies, primarily of
knockout animal models and cell culture, uncovered networks of PPARγ and PPARδ, their heterodimeric RXR partners, associated
transcriptional coactivators, and target genes, that regulate various aspects of placental development and function. These studies
furnish both specific information about trophoblasts and the placenta and potential hints about the functions of PPARs in other
tissues and cell types. They reveal that the remarkable versatility of PPARs extends beyond the orchestration of metabolism to the
regulation of cellular diﬀerentiation, tissue development, and trophoblast-specific functions. This information and its implications
are the subject of this review.
Copyright © 2008 Yaacov Barak et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1.

INTRODUCTION

Mammalian reproduction entails prolonged gestation, posing the challenge of securing the thrift and long-term survival
of the fetus in utero. The evolutionary answer to this challenge has been the emergence of the placenta, whose roles
are to facilitate eﬃcient nutrient, gas and waste exchange between the mother and fetus, while conferring immune privilege on the embryo and secreting pregnancy hormones. The
placental core comprises a dense vascular array, where maternal and fetal circulations run in close proximity, but are
strictly separated by a trophoblast barrier that specializes in
essential bidirectional metabolite transport into and out of
the fetus. Placental dysfunction is associated with common
disorders of pregnancy, including spontaneous abortions,
intrauterine growth restriction (IUGR), and preeclampsia,
all of which are commonly associated with compromised
placental vasculature [1–3]. In the mouse, dozens of targeted gene mutations result in placental defects that underlie
stunted growth or midgestation lethality (reviewed in [4, 5]).
Proof of direct causative relationship between such defects
and the lethal outcome comes from the complete rescue of
embryos by selective reconstitution of the trophoblast in several knockout mouse strains [6–12].

Among the genes whose deficiency results in lethal placental defects are PPARγ and PPARδ; the two are closely related, yet functionally distinct members of the nuclear hormone receptor superfamily of ligand-activated transcription
factors. Obligate heterodimers of PPARs and retinoid X receptors (RXRs) bind to PPAR-response elements (PPREs) in
the cis-regulatory regions of target genes and activate transcription in response to small lipophilic ligands. While the
identities of endogenous PPAR ligands are still inconclusive, pharmaceutical development has yielded several highaﬃnity synthetic agonists that are widely used in both the
clinic and the lab. Importantly, notwithstanding the primary
focus of the PPAR field on cellular and systemic metabolism,
PPARs and their associated regulators play at least equally essential roles in placental development and function, as reviewed below.
1.1.

Placental development and
trophoblast differentiation

The deepest insights into the functions of PPARs in the placenta have been provided by mouse genetic studies. This
succinct overview and the accompanying Figure 1 aim at
providing the framework for these studies by summarizing
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placental development in mice. One should bear in mind that
while basic principles and molecular regulation of placental
development and function are similar across mammals, morphological patterning and architecture of the placenta, and
hence terminology, vary considerably among species.
With the exception of the percolating maternal blood,
the placenta is exclusively an embryonic tissue. The juxtaposed decidua is a maternal tissue formed from endometrial lining of the uterus. The placenta is comprised of trophoblast cells that originate from the trophectoderm layer of
the blastocyst (Figure 1). Implantation of the embryo into
the uterine wall triggers the expansion and initial diﬀerentiation of trophectoderm cells to form both the chorion and,
by process of endoreduplication, primary giant cells. These
giant cells facilitate uterine invasion by the embryo. The
chorion harbors trophoblast stem cells and, in the mouse,
gives rise to the ectoplacental cone (EPC). After initial expansion, the EPC yields the spongiotrophoblast layer and
secondary giant cells (Figure 1). Giant cells separate the placenta from the maternal decidua and are responsible both
for maintaining the tight placenta-decidua interface and for
executing various endocrine functions, including secretion
of steroid and prolactin family pregnancy hormones. Spongiotrophoblasts perform (a) endocrine functions by secreting pregnancy specific glycoproteins (PSGs) and prolactinrelated hormones, (b) metabolic functions, such as glycogen
storage and production of IGF2, and (c) presumed mechanical support functions. Syncytiotrophoblasts that comprise
the hemochorial trophoblast barrier between maternal and
embryonic circulations (the labyrinthine layer in mice; floating chorionic villi in humans) originate directly from the
chorion. In the mouse, vascularization of the placenta initiates around E8.5, when the allantois, which harbors the future umbilical blood vessels, attaches to the chorionic plate.
Subsequently, the chorioallantois invaginates into the placenta and lays the vascular framework of the labyrinth. Concomitantly, chorionic trophoblasts in the labyrinth diﬀerentiate into three morphologically and functionally distinct
single cell layers that form a highly specialized epithelial barrier, which execute all bidirectional transport functions between the mother and the fetus. Insights from mouse mutants demonstrate that formations of the labyrinthine trophoblast and placental vascularization are highly concordant
and involve extensive cellular and molecular interactions between the allantoic endothelium and the trophoblast [4]. The
trophoblast is crucial for placental vascularization, as evident
from the complete correction of diverse placental vascular
defects by trophoblast-selective rescue [8–12]. In turn, multiple signaling factors secreted by the embryonic endothelium,
such as HGF, EGF, LIF, PDGFB, and WNT-2, are essential for
proper formation of the labyrinth [13–20].
Cell culture studies have facilitated the mechanistic understanding of molecular and cellular processes involved in
various aspects of trophoblast diﬀerentiation and function.
This area has been markedly advanced by the successful establishment of protocols for procuring and manipulating
trophoblast stem (TS) cells from blastocysts or the EPC [21].
The stem cell status of TS cells can be maintained by FGF4
and embryonic fibroblast-derived factors, possibly related to
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TGFβ or activin [21, 22]. When FGF and conditioned media are withdrawn from the culture medium, mimicking
the growing distance between distal trophoblast layers and
the embryonic FGF4 source, TS cells diﬀerentiate spontaneously, primarily into giant cells and to some extent also
into spongiotrophoblast and multinucleated syncytial cells
[21, 23]. Moreover, when reintroduced into blastocysts, TS
cells are able to diﬀerentiate into all trophoblast derivatives
[21], demonstrating their true stem cell nature.
2.

PPARγ

In the absence of prior evidence that PPARγ is expressed during early embryogenesis, the death of Pparg-null embryos at
the 10th day of gestation (E10.0) was initially surprising [12].
However, further inquiry revealed that Pparg is expressed
abundantly in the placenta from E8.5 onward, and is not detected in any other embryonic tissue until at least E13.5 (12).
This expression pattern provided circumstantial evidence
that PPARγ may function in the placenta, but the survival
of tetraploid chimeras provided the definitive proof that placental PPARγ deficiency was the cause of embryonic lethality [12]. Tetraploid chimeras are generated by electrofusing 2-cell embryos into single cells with tetraploid genomes.
Such embryos resume development, and their aggregation
with diploid morulas or embryonic stem cells gives rise to
chimeras whose embryo derives exclusively from the diploid
partner while their placentas derive from the tetraploid partners [24]. When used to reconstitute diploid Pparg-null embryos with WT tetraploid placentas, this procedure allowed
survival of the mutant embryos until birth, when they succumbed to unrelated defects that included severe cerebral
and intestinal hemorrhages [12]. The recent availability of
epiblast-specific Cre transgenes, which delete loxP-flanked
(floxed) alleles eﬃciently in the embryo but not extraembryonic tissue, has enabled to reprove this notion by demonstrating that near-complete deficiency of Pparg in the embryo proper is not embryonic lethal [25, 26].
2.1.

PPARγ and trophoblast differentiation

The complex histological and ultrastructural phenotype of
Pparg-null placentas (Figure 2) provided insights into the essential functions of PPARγ. Expression and spatial distribution of prototypic trophoblast lineage markers are intact in
the mutant placentas, including the giant cell layer, the spongiotrophoblast, the labyrinth, and the chorion [12]. However, labyrinthine trophoblast precursors fail to terminally
diﬀerentiate, and instead, retain parenchymal morphology
without undergoing either compaction or syncytium formation [12]. The basement membrane between the trophoblast
and fetal endothelium is severely disrupted, loosening the
critical tight association between the two cell types [12]. This
defect likely hampers both the flow of metabolites from the
trophoblast to the embryo and the ability of embryonic vessels to use basement membrane tracks for extending and
branching into the labyrinth. Consequently, fetal vessels do
not permeate the Pparg-null placenta and the labyrinthine
layer does not eﬀectively form [12]. The trophoblast-lined
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Figure 1: Trophoblast lineages in the developing mouse placenta. Shown from left to right are a blastocyst (E3.5), an E6.5 embryo, and an
E9.5 embryo. Respective trophoblast lineages are traced for clarity. Al: allantois; Ch: chrion; CP: chorionic plate; De: decidua; Emb: embryo;
EPC: ectoplacental cone; 1◦ GC: primary giant cells; 2◦ GC: secondary giant cells; ICM: inner cell mass; La: labyrinth; Sp: spongiotrophoblast;
TE: trophectoderm. FGF4: fibroblast growth factor 4 secreted by the embryo to maintain the chorion. Blastocyst and E6.5 embryo picture
courtesy of Drs. Mimi DeVries and Tom Gridley, respectively, The Jackson Laboratory.

maternal blood pools are dilated and ruptured, leading to
hemorrhages, fibrin deposition, and overt phagocytosis of
maternal erythrocytes by junctional zone trophoblasts [12].
Together, these observations indicate that while PPARγ is dispensable for partition of trophoblasts to diﬀerent lineages, it
is essential for terminal diﬀerentiation of labyrinthine syncytiotrophoblasts and spongiotrophoblasts, and in turn for
placental vascularization and integrity. The further increase
of Pparg levels in the labyrinth during late gestation suggests
that beyond its role in establishing the vascular network of
the placenta it may also play an important role in its elaboration and maintenance [27].
On the opposite pole of the PPARγ spectrum, feeding
pregnant mice a high dose of the PPARγ agonist rosiglitazone
(rosi) from mid to late gestation elicited severe thinning of
the spongiotrophoblast layer and substantial dilation of the
maternal blood pools in WT placentas [28]. Pparg+/− placentas were protected from these eﬀects, indicating that these
are indeed the result of excessive PPARγ activity. Reduced expression of the trophoblast stem cell marker Eomes in rositreated WT placentas [28] suggested that excessive PPARγ
activity might cause these eﬀects by accelerating stem cell differentiation, concomitantly depleting the stem cell pool and
destabilizing the balance between diﬀerentiated trophoblast
cell types in the placenta. Warnings about embryonic toxicity in rats in the inserts of two commonly prescribed PPARγ
agonists, Avandia (rosi) and Actos (pioglitazone), may reflect similar phenomena. In contrast, short-term administration of acute doses of rosi to pregnant rats during midgestation or chronic exposure of pregnant mice to moderate doses
of rosi was harmless [29, 30], as were anecdotal incidents
in which pregnant women were accidentally exposed to the
drug [31, 32].
The functions of PPARγ in trophoblast diﬀerentiation
have been simulated in several in vitro systems. For example,
stimulation of primary human term trophoblasts by PPARγ

agonists enhanced their diﬀerentiation into multinucleated
syncytiotrophoblasts, in agreement with the critical role of
PPARγ in syncytium formation in the mouse labyrinth [33].
In TS cells, the association of PPARγ with trophoblast diﬀerentiation is manifested in its dramatic induction during transition from the undiﬀerentiated to the diﬀerentiated state
[34]. This pattern demonstrates that PPARγ is integral to the
process of trophoblast diﬀerentiation and pinpoints TS cells
as an ideal platform for studying the placental functions of
PPARγ. On this front, we recently established Pparg-null TS
cell lines, whose analysis is currently underway [35].
2.2.

PPARγ and trophoblast metabolism

The established roles of PPARγ in systemic and cellular energy metabolism and the importance of trophoblast
metabolism for embryonic development raised the plausible hypothesis that PPARγ might regulate metabolic functions of trophoblasts. This idea was strongly supported by the
near-complete absence of lipid droplets from the fetal vesselproximal trophoblast layer of Pparg-null placentas as opposed to their WT counterparts, in which these droplets are
abundant [12]. Moreover, PPARγ and RXR agonists synergistically stimulate lipid uptake in both cultured trophoblasts
in vitro and whole placentas in vivo [28, 36]. These processes
are associated with the upregulation of CD36, FABPpm, fatty
acid transport proteins 1 and 4 (Fatp1, Fatp4), and the lipid
droplet proteins adipophilin, S3-12, and MLDP [28, 36].
Thus, PPARγ is an important regulator of lipid dynamics in
trophoblasts.
Hypoxia of trophoblasts due to hypoperfusion of the
placental bed is a common complication in human pregnancy. Interestingly, agonist-mediated stimulation of PPARγ
protects trophoblasts from an acute, but not a long-term
apoptotic response to hypoxia [37]. Potential mechanisms
underlying this protective eﬀect include PPARγ-dependent
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Figure 2: Schematic representation of the Pparg-null phenotype. (a) WT placenta. Al: allantois; Ar: maternal artery; Ch: chorion; De: decidua; FV: fetal blood vessels; La: labyrinth; MBP: maternal blood pools; Sp: spongiotrophoblast; TGC: trophoblast giant cells. (b) Pparg-null
placenta. Corresponding structures are as in (a). Diﬀerences of note are marked erythrophagocytosis by spongiotrophoblast cells (red speckles), absence of fetal vessels and breakdown of the maternal blood pools in the labyrinth, and thickening of the chorion. (c,d) Ultrastructural
features of WT and Pparg-null hemochorial barriers (based on [12]). See legend in (c) for identity of major features. Diﬀerences include
thickening of the three trophoblast layers, near elimination of lipid droplets in layer III, and loosening of the tight adherence between the
trophoblast (green) and fetal endothelium (orange).

diﬀerentiation of cytotrophoblasts to syncytiotrophoblasts,
which are more resistant to hypoxic death, or direct inhibition of apoptotic pathways by PPARγ.
2.3. Other PPARγ functions in trophoblasts
In addition to the role of PPARγ in trophoblast diﬀerentiation and metabolism, it appears to contribute to specialized functions of trophoblasts. One of these unique func-

tions is invasion of the endometrium. The strong coexpression of PPARγ and its obligatory RXRα partner in extravillous cytotrophoblasts at the maternal-fetal interface of human embryos suggested that PPARγ might regulate the invasive functions of trophoblasts. The ability of PPARγ and RXR
agonists to inhibit matrigel invasion by both primary and
transformed trophoblasts, and the enhancement of invasion
by PPARγ and RXR antagonists, supported this hypothesis
and implicated PPARγ as a negative regulator of the process
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[38, 39]. This activity has been correlated to a 3-fold decrease
in the expression of pregnancy-associated plasma protein A
(PAPP-A)—a protease essential for maturation of the proinvasive IGF2—and to a 3-fold induction of Interleukin-1β
[40].
Another critical function of trophoblasts is the secretion
of reproductive hormones, such as placental lactogens (PL)
and choriogonadotropin (hCG). Studies in primary human
trophoblasts showed that PPARγ and RXR agonists stimulate hCG and hPL production, and that PPARγ-RXRα heterodimers directly activate hCGβ via a PPAR-response element (PPRE) in its promoter [33, 38]. These findings suggest
that PPARγ functions extend to trophoblast-specific processes beyond cell diﬀerentiation, metabolism, and motility.
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the details of native gene regulation by PPARs. Our studies
of the Muc1 promoter provide an excellent example for the
unique insights that such an approach can provide over the
study of synthetic promoters or isolated response elements.
A proximal Muc1 promoter fragment responds robustly and
in an RXRα-dependent manner to PPARγ and rosi, yet unlike most previously studied PPAR targets, let alone synthetic
ones, is entirely refractory to PPARα and PPARδ [34]. Detailed mutation analyses reveal a weak PPRE in the proximal
part of the Muc1 promoter that acts as a basal silencer, and
whose derepression by PPARγ is required for robust and specific induction of Muc1 by an upstream, non-PPAR-binding
enhancer [34]. This level of detail reveals previously unappreciated layers of specificity and intricacy underlying the
regulation of real-life targets by PPARγ.

2.4. Placental PPARγ target genes
PPARs are transcription factors, and as such, their raison
d’être is to regulate the expression of target genes. Identification of these targets is therefore fundamental for determining the biological functions of PPARs. Two primary
philosophies underlie target gene identification. The first is a
candidate gene approach, which involves hypothesis-driven
testing of genes that make plausible targets based either on
their established regulation by PPARs in other tissues or on
their known relationship to PPAR-regulated processes; trophoblast targets of PPARs found via this approach are described throughout this review in relation to their biological context. The second approach is discovery-based, and
involves unbiased, transcriptome-wide screening for target
genes based on genetic, pharmacological, and biochemical
criteria. The strength of this strategy lies in its ability to
break ground and identify targets whose regulation by PPARs
would not be otherwise hypothesized.
The identification of Muc1 as a PPARγ target gene in trophoblasts by subtraction of cDNA from WT versus Ppargnull placentas has proven the power of the latter approach to
unearth unexpected targets [34]. Muc1 is very tightly regulated by PPARγ, and its expression is lost in both Pparg-null
and Rxra-null placentas and is upregulated by PPARγ agonists in both diﬀerentiated TS cells and whole WT placentas
[28, 34]. The Muc1 protein localizes to apical labyrinthine
trophoblasts surrounding maternal blood pools, analogous
to its luminal localization on simple secretory epithelia, such
as those that abut milk or salivary ducts [34]. This spatial pattern invokes unanticipated anatomical and functional analogies between trophoblasts and prototypic luminal epithelia,
raising the provocative idea that some of the placental functions of PPARγ are a carryover from more ancient functions
in classical epithelia. However, unlike Pparg, Muc1 is not essential for placental development and its deficiency leads at
worst to a mild dilation of the maternal blood pools in the
labyrinth [34]. This benign phenotype indicates that other
target genes must account for the essential placental functions of PPARγ. Our ongoing microarray-based screens start
to uncover new PPARγ targets that may account for these
functions [35].
In addition to their prospect in illuminating PPAR functions, new target genes provide novel templates for studying

2.5.

PPARγ and the placenta-heart axis

Analysis of Pparg-null embryos unexpectedly found accelerated cardiomyocyte diﬀerentiation and thinning of the ventricular wall [12, 41]. This observation was intriguing because at that developmental stage Pparg is expressed nowhere
but in the placenta. Consistent with this expression pattern, complete reversal of the cardiac defects in Pparg-null
tetraploid chimeras confirmed that these anomalies are secondary to the placental defects [12]. This result invoked a
previously unappreciated dependence of early heart development on placental integrity [12]. How placental Pparg
deficiency underlies cardiac malformation is currently unclear and could involve generalized nutritional, vascular, or
metabolic deficiencies, hypoxia, or a deficiency for placentaderived factors. However, similar cardiac defects are often
observed in association with placental anomalies (reviewed
in [42]), and the “placenta-heart axis” has been since reinforced in p38a-null embryos, which phenocopy the Ppargnull placental and cardiac defects and are similarly rescued
by tetraploid chimeras [11]. Therefore, myocardial failure is
likely a general attribute of placental insuﬃciency and not a
specific consequence of PPARγ mutation.
3.

PPARδ

As in the case of PPARγ, the finding that Ppard-null embryos succumb to lethal placental defects was also unexpected [43, 44]. The first Ppard-null mouse strain reported
was generated by truncating the gene a mere 60 amino acids
from its C-terminus (Ppard-ΔC60), leaving the entire DNAbinding domain and most of the ligand-binding domain intact [45]. While this allele is likely a hypomorph, the authors
reported significantly smaller size and lower survival rates of
the original F2 homozygotes for this allele, which they have
overcome by outbreeding and consecutive mating of the survivors [45]. In contrast, mice in which PPARδ was inactivated by CRE/loxP-mediated truncation of the N-terminal
half of the DNA-binding domain and frame-shifting of the
remaining 3’ part of Ppard mRNA exhibited overwhelming embryonic lethality and placental defects, as detailed in
Section 3.1 [43]. Nevertheless, a few homozygous-null mice
survived gestation thanks to a complex influence of genet-
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ics and maternal physiology (see Section 3.2). Two other
null configurations, one with lacZ insertion into the DNAbinding domain of PPARδ [46, 47] and another that replaced
the DNA-binding domain with PGK-neo [44], yielded identical lethality and placental defects, confirming that PPARδ is
indeed essential for placental function.
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3.1. PPARδ in placental development and integrity
Lethality and sub-Mendelian ratios of Ppard-null embryos
are observed from E9.5–10.5 onward. Rare null embryos surviving beyond that stage typically exhibit severe flooding of
maternal blood into the placental and embryionic space, are
significantly smaller than their WT and heterozygous siblings, and the few that survive to birth are markedly runt
[43, 44]. Still, none dies after birth and all thrive and become generally healthy and fertile adults, despite remaining
slightly smaller than their Ppard suﬃcient counterparts [43].
The combination of strictly prenatal mortality, growth restriction, and abundant expression of Ppard in the placenta
points to critical defects in extraembryonic tissue.
From as early as E8.5 onward, Ppard-null embryos and
placentas are significantly smaller than their littermates [43,
44]. All placental compartments are smaller, including the
labyrinth, the spongiotrophoblast, and the giant cell layer.
The latter is severely thinner and discontinuous, with cells
that do not attain the maximal size typical of WT giant cells
(43, 44). This compromise in giant cell size and continuity likely underlies the observed loosening of the normally
tight placenta-decidua interface and the inability to retrieve
Ppard-null specimens from E9.5 onward without substantial detachment of placentas from the deciduas [43]. In contrast, while the labyrinth is smaller, its vascular structure is
fully elaborated, clearly distinguishing the Ppard-null from
the Pparg-null placental phenotype [43]. These features are
summarized schematically in Figure 3.
Consistent with the implicated role of PPARδ in giant cell diﬀerentiationin vivo, studies of the trophoblast cell
line Rcho-1 have unequivocally demonstrated that PPARδ is
crucial for giant cell diﬀerentiation in vitro [44]. Agonistmediated stimulation of PPARδ dramatically accelerated differentiation of Rcho-1 cells into giant cells, whereas siRNAmediated knockdown of PPARδ severely inhibited the process. PPARδ was necessary and suﬃcient for suppression of
Id-2, which inhibits giant cell diﬀerentiation, and for upregulation of I-mfa, which promotes giant cell diﬀerentiation by antagonizing the bHLH transcription factor Mash2. Interestingly, in trophoblasts, just like in keratinocytes,
PPARδ upregulates the expression of two key nodes in the
PI3 kinase (PI3K)/Akt signaling pathway: PDK1 and ILK.
These, in turn, activate Akt by phosphorylating two residues:
Thr308 and Ser473. Activation of this pathway is critical for
the ability of PPARδ to accelerate giant cell diﬀerentiation,
and a synthetic PI3K inhibitor completely reversed upregulation of PL-1, downregulation of Id-2, and giant cell formation. However, additional pathways are at play downstream
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Figure 3: Schematic representation of the Ppard-null phenotype.
(a) WT placenta (similar to Figure 2(a)). (b) Ppard-null placenta.
Hr: hemorrhage; for all other abbreviations see the legend for Figure 2. Notable diﬀerences include smaller and discontinuous giant
cells, reduced size of the entire placenta and loosening of its attachment to the decidua, and sporadic severe hemorrhages at various
locations in or around the placenta.

of PPARδ, as evident in the insensitivity to PI3K inhibition
of PPARδ-dependent I-mfa activation.
3.2.

Genetic and maternal modifications of
the Ppard-null phenotype

Surprisingly, all Ppard deficient alleles exhibit highly variable
penetrance of both the placental phenotype and lethality itself. Our early studies of Ppard-null mice encountered a clear
maternal eﬀect on the fate of Ppard-null embryos. These
studies were carried out on either a pure 129/SvJae 129 background or a segregating F2, F3, and F4-C57BL/6J [B6]: 129
background, in which the vast majority of homozygous null
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embryos die during gestation [43]. However, 2–5% of 129Ppard-null mice and 10–15% of B6: 129-Ppard-null mice
survived to parturition. These rare survival events were not
randomly distributed. First, litters with multiple null pups
(up to 4 in one litter) were frequently observed [43, 47].
Second, all survival cases occurred in first-time pregnancies,
none recurring in the same breeding pair. Third, survival was
not heritable in these cases, that is, null mice were fully fertile, but never gave birth to Ppard-null progeny when crossed
with Ppard+/− or Ppard−/− mates. This substantial deviation
from random distribution suggested that survival on these
genetic backgrounds is modified primarily by maternal conditions rather than genetics. A hypothetical example of such
conditions is slow immune attack of first-time mothers on
embryos with breached immune privilege.
Notwithstanding maternal eﬀects, the Ppard-null phenotype is also clearly subject to genetic modification. Peters et
al. alluded to poor survival of the initial batch of homozygous Ppard-ΔC60 mice and the complete resolution of this
problem by an additional backcross of F1 mice with inbred
C57BL/6N mates, which yielded normal Mendelian distribution of the progeny starting at F3 [45]. Similarly, Nadra
et al. reported very low survival rates of outbred B6:129Ppard-null mice, which was eventually overcome by intercrossing rare surviving mutants [44]. Our work in progress
sheds further light on the eﬀects of genetic modifiers on the
Ppard-null phenotype. First, repetitive backcrosses onto B6
completely obliterates survival of mutants beyond E9.5, indicating that 129-specific alleles allow mutants to survive 1-2
days longer than B6 alleles and are more permissive towards
the survival of Ppard-null embryos to term [47]. Second,
when B6:Ppard+/− mice are backcrossed onto an FVB/NJ
(FVB) background, intercrosses of the heterozygous F1 generation result in survival of ∼15% of the expected Ppard-null
progeny [47]. On this background, survival of F2 FVB:B6Ppard-null mice is evenly distributed and not limited to first
time pregnancies. Thus, FVB alleles are permissive for survival of Ppard-null embryos, yet in a substantially diﬀerent
way than the 129 or B6:129 backgrounds. Third, survival of
FVB:B6 Ppard-null embryos is heritable, and multigenerational intercrosses of F2-FVB:B6-Ppard-null parent pairs and
their progeny led to the establishment of a semistable stock of
viable Ppard-null mice [47]. This stock has reached a reproductive plateau by F4, and now consistently yields survival
of approximately 50% of the Ppard-null progeny. Further inspection reveals that all progeny survive to E10.0, when approximately half of the litter develops abnormal histological
features at the placenta-decidua interface and succumbs to
transplacental infiltration of maternal blood and fatal hemorrhaging and necrosis. In contrast, the placentas of viable
Ppard-null embryos from this stock are broadly normal. At
present, it is not clear whether this sharp partition represents
a stochastically incomplete penetrance or rather a discrete genetic or epigenetic modifier that is inherited by only 50% of
the progeny.
In conclusion, placental PPARδ regulates essential processes, which are highly interactive with the genetic and maternal environments. Further studies of the Ppard-null phenotype, its response to experimentally defined maternal vari-
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ables, and identification of genes that modify its nature and
outcomes should yield new insights into the biology of both
PPARδ and the placenta.
4.

TRANSCRIPTIONAL PARTNERS OF PPARS

The ability of PPARs to bind DNA and activate transcription depends strictly on heterodimerization with retinoidX receptors (RXRs) [48]. In addition, diverse transcriptional
coactivator proteins are indispensable for transcriptional activation by PPAR-RXR heterodimers. These interdependencies imply that both RXRs and relevant coactivators should
be essential for placental functions of PPARs and their deficiencies should yield comparable phenotypes.
4.1.

RXRs

RXRα is the major RXR isoform in the placenta [49], and
its deficiency is therefore expected to recapitulate lethal placental defects of Pparg-null and Ppard-null embryos. Indeed,
Rxra-null placentas exhibit multiple defects, some of which
are similar to defects in Pparg-null placentas, including the
following: (a) incomplete compaction of labyrinthine trophoblasts, (b) disruption of the basement membrane and
the tight contact between labyrinthine trophoblasts and infiltrating fetal endothelium, (c) a marked reduction in lipid
droplet content of labyrinthine trophoblasts, and (d) maternal hematomas at the junctional zone [50]. Other defects,
such as partial disorganization of the labyrinthine zone, invasion of spongiotrophoblast cells into the labyrinth, and reduced number of glycogen cells, are not an obvious extrapolation of either the Pparg-null or the Ppard-null phenotype.
Still, Rxra-null embryos die between E12.5 and E16.5
[51, 52], and the aforementioned placental anomalies are observed later than the lethal endpoints of either PPAR deficiency. Therefore, these defects can represent at best an incomplete knockdown of PPARγ and δ activities. This milder
phenotype is apparently rooted in functional redundancy
with RXRβ, as evident in the markedly accelerated and exacerbated Rxra/Rxrb double null phenotype [53]. Rxra/b double null embryos die at E9.5 while exhibiting a combination
of failed placental vascularization, which is a hallmark of
Pparg deficiency, and severe placenta-decidua detachment,
as in Ppard-null embryos. This phenotype suggests that although RXRα is the primary PPAR partner in the placenta,
RXRβ provides a redundant, albeit incomplete backup for
PPAR function in the placenta.
The most conspicuous phenotype of Rxra-null embryos
is severe thinning and incomplete septation of the cardiac
ventricles, which is the likely cause of their death [51, 52].
This phenotype is non-cardiomyocyte-autonomous [54] and
has been successfully recapitulated by ablation of retinoic
acid signaling in the epicardium [55]. Consequently, its relationship to the placental defects has never been investigated.
Nevertheless, the proven dependence of myocardial hypoplasia on placental defects in Pparg-null embryos raises the need
to examine whether at least some aspects of the cardiac Rxranull phenotype can be traced back to placental defects.
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4.2. CoActivators
Among the large array of cofactors that mediate transactivation functions of PPAR-RXR heterodimers, two stand out in
the context of placental functions: PBP/DRIP205/TRAP220
(oﬃcial gene name: Pparbp) and PRIP/AIB3/RAP250 (official name: Ncoa6). Three teams knocked out Pparbp and
found that homozygous null embryos die at E11.5 concomitant with growth restriction and myocardial hypoplasia [56–
58]. One team described placental defects that included poor
compaction of labyrinthine trophoblasts, reduced vascularization, and phagocytosis of maternal erythrocytes, recapitulating multiple histological and ultrastructural features
of Pparg-null placentas [56]. These observations suggested
that PPARBP coactivates essential developmental targets of
PPARγ-RXRα/β heterodimers in the placenta, and the later
lethality of these mutants suggested partial redundancy with
other coactivators. A second team saw no overt morphological defects in Pparbp-null placentas, but found that tetraploid
chimeras postponed lethality of the mutants from E11.5 to
E13.5, proving that the homozygous-null embryos nevertheless die due to placental defects [57]. Interestingly, tetraploid
chimeras did not rescue the cardiac defects of Pparbp-null
mice, demonstrating that these defects evolve irrespective of
the placental problems, unlike in the case of Pparg deficiency.
Three teams of investigators generated and analyzed
diﬀerent Ncoa6-null mouse strains that exhibited diﬀerent
grades of phenotypic severity [59–61]. One team targeted
Ncoa6 by deleting exons 4 through 7 [59]. Homozygousnull embryos died around E10.0, preceded by substantial
growth restriction, severe myocardial thinning, and a series
of placental defects that closely resembled those of Ppargnull placentas. These included (a) failed vascularization of
the labyrinth, (b) poor compaction of syncytiotrophoblasts,
(c) dilation and rupture of the maternal blood pools, and
(d) erythrophagocytosis in the junctional zone. An additional placental phenotype not shared with Pparg-null placentas was thickening of the giant cell layer alongside thinning of the spongiotrophoblast and the labyrinthine zones
[59]. These overall similarities indicated that Ncoa6 is critical for the essential transcriptional functions of PPARγ and
perhaps additional transcription factors in the placenta and
that Ncoa6 deficiency is not compensated for by genetic redundancy. The other two teams interrupted the gene downstream of exon 6, and reported undetectable levels of Ncoa6
gene products, but a significantly milder phenotype [60, 61],
which suggested that both configurations are functional hypomorphs. Homozygous-targeted embryos for these alleles
died around E13.5 and exhibited myocardial hypoplasia and
placental defects that included a thin spongiotrophoblast
layer, ectopic spongiotrophoblasts within the labyrinth, reduced vascularization of the labyrinth, and stasis and necrosis in the junctional zone [60, 61]. Interestingly, these features
are highly reminiscent of the Rxra-null phenotype, suggesting that they indeed reflect incomplete loss of Pparg function.
While the phenotypes of Ncoa6 and Pparbp-null mice
pinpoint the two as essential coactivators of PPARγ-RXRα/β
transcription complexes in the developing placenta, this is by
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no means the complete inventory of cofactors that are crucial
for placental functions of PPARs. First, no cofactor knockout
has so far yielded a Ppard-null-like phenotype. Second, possible roles of cofactors that have not yielded clear placental
phenotypes cannot be ruled out. For example, mice deficient
for either CBP or p300 die during early gestation [62–64],
and because extraembryonic tissues were not carefully examined in these mutants, placental defects are still a strong
possibility. Another complication is presented by families of
homologous cofactors with a high potential for functional redundancies, such as the p160 coactivators SRC-1, TIF2, and
ACTR/SRC-3 or the PGC-1 family, that is, PGC-1α, PGC-1β,
and PRC. While single deficiencies for any of these cofactors
are not embryonic lethal, therefore precluding serious placental defects, one should keep in mind that compensation
by remaining family members may well be at play.
5.

CONCLUSIONS AND PROSPECTS

As detailed in this review, PPARγ and PPARδ play nonredundant roles in placental development and physiology.
PPARγ is a key regulator of trophoblast diﬀerentiation and
metabolism, PPARδ is essential for giant cell function and
placental integrity, and their coreceptors RXRα and β are instrumental for the execution of these functions. At least two
transcriptional coactivators, PPARBP and NCOA6, are critical for essential functions of PPARγ in the placenta, as deduced from the Pparg-null-like phenotype of their deficiencies, and additional cofactors are likely crucial for those of
PPARδ.
Still, the network of signals upstream, alongside, and
downstream of PPARγ and PPARδ is far from elucidated.
Several PPAR targets have been identified in trophoblasts,
providing initial mechanistic insights into PPAR function in
the placenta. However, the discovery of as many new target
genes will be indispensable for fully deciphering these functions. Another important eﬀort should be to determine the
various regulators that control or modify PPAR expression
and activity in trophoblasts. These include, but are not limited to upstream transcriptional regulators, molecules that
control the stability of PPAR gene products, posttranslational
modifications that alter the functions of PPARs, RXRs, or
their cofactors, and the production and dissemination of
endogenous ligands. Many of these processes may constitute key regulatory nodes in placental physiology. In addition, PPAR-specific features, such as the identity of genes that
modify the outcomes of PPARδ deficiency, would provide invaluable insights.
Finally, identifying compelling similarities between the
Ppar-null placental phenotypes and published descriptions
of targeted genes with previously unknown connections
presents a complementary approach for identifying critical
nodes in placental PPAR signaling. Such a strategy has been
widely successful in identifying a plethora of epistatic relationships in lower eukaryotes such as yeast, nematodes, and
flies, and more recently in identifying novel SHH signaling components in mice [65]. Because placental defects are
among the earliest roadblocks in the development of many
gene-targeted embryos, such opportunities abound. For ex-
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ample, the published analyses of single and compound keratin 8 (mK8), mK18, and mK19 knockouts reveal remarkable
similarities to the Ppard-null placental phenotype [66–69].
Similarly, the placental and cardiac phenotypes of αV- and
β8-integrins, p38α, JunB, and Fra1 knockouts are strikingly
similar to those of Pparg-null embryos [9–11, 70, 71]. Integrating studies of these genes and their corresponding pathways into the functional studies of PPARs and their regulators, associated factors, and transcriptional targets should
provide further insights into the mode by which PPAR signaling networks regulate placental development.
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